Scope and Claims of US Patent 8,771,739: Itraconazole Solid Dispersion With HPMCP to Boost Exposure and Reduce Food Effect

US Drug Patent 8,771,739 is directed to a specific itraconazole solid-dispersion system: itraconazole dispersed with hydroxypropyl methylcellulose phthalate (HPMCP), with particle-size/cloudiness characteristics that persist through filtration, and an in vivo exposure target (mean AUC ≥800 ng·h/mL for 100 mg itraconazole in the fasted state). The claim set spans (1) composition, (2) particle/suspension appearance and size distributions, (3) in vitro dissolution test conditions including pH and acid pre-treatment, (4) manufacturing by spray drying and specified solvents, and (5) dosage forms and processes for preparation.

What is US Patent 8,771,739 about and what claims define the protected itraconazole composition?

Core subject matter (Claim 1): A pharmaceutical composition that is a solid dispersion of itraconazole and a polymer with acidic functional groups, where the polymer is hydroxypropyl methylcellulose phthalate (HPMCP). During in vitro dissolution testing, the composition forms a suspension that maintains a homogeneous dispersion of particles. The itraconazole-to-polymer ratio is 1:1 to 1:3. The formulation is tied to a performance benchmark: it provides a mean AUC ≥800 ng·h/mL after administration of itraconazole in the fasted state.

Stated dependencies and performance tethering: Many downstream claims are narrower variations of Claim 1, but they all retain Claim 1’s structural and performance anchors: HPMCP solid dispersion, defined ratio, suspension-based behavior in dissolution testing, and the AUC target language appears in Claim 1 and a parallel tighter version appears in Claim 25.

Key claim elements to map to infringement risk

Material pair: itraconazole + HPMCP (acidic functional polymer).
Solid dispersion architecture: itraconazole dispersed in HPMCP as a solid dispersion, not just a simple blend.
Ratio window: itraconazole:polymer 1:1 to 1:3.
In vitro dissolution behavior: forms a suspension of a homogeneous dispersion of particles.
Particle-size and appearance constraints: cloudiness maintained; submicron and nano ranges; retained cloudiness after 450 nm filtration.
Test-condition tie-ins: pH ranges and optional acid pre-treatment (pH ~1.2 for ~20 minutes).
Manufacturing constraints: spray drying; optional specified solvents; and (in the dependent process claims) solvent and blending specifics.
Dosage form inclusion: capsule or tablet containing a therapeutically effective amount of the Claim 1 composition.

Which polymers and excipients are explicitly required under US 8,771,739?

Does the patent require HPMCP specifically?

Yes. Claim 1 specifies the polymer comprises hydroxypropyl methylcellulose phthalate. No other acidic functional polymer is substituted in the independent claim.

Is there an explicit excipient list for the protected dosage form?

Yes for dependent claim territory:

Claim 16 includes excipients selected from disintegrants, diluents, fillers, lubricants, glidants, colorants, flavors.
Claims 15-18 define a dosage form containing therapeutically effective amounts of the Claim 1 composition, and specify capsule or tablet.

Business implication: Even with excipients allowed, the claims still require that the dosage form contains the protected Claim 1 solid dispersion.

What does US 8,771,739 require about particle size, “cloudy suspension” behavior, and filtration?

The claim set tightly operationalizes the suspension and particle morphology through measurable features.

Cloudiness and diffraction

Claim 2: Particles diffract light such that the suspension presents as a cloudy suspension, and particle size is <10 micrometer and >1 nm.

Mixed microparticulate and nanoparticulate populations

Claim 3: Particles include both microparticulate and nanoparticulate fractions.

Retained cloudiness after 450 nm filtration

Claim 4: Particles include sizes <450 nm and >1 nm such that after passing the suspension through a 450 nm filter, the suspension remains cloudy.

Business implication: A generic or follow-on product that eliminates the nano fraction or yields a clear filtrate at 450 nm may fall outside these dependent claims, but Claim 1 could still be asserted if the core solid dispersion and AUC target are met. Conversely, a product meeting Claim 1 but with different particle distribution could still avoid several dependent claims.

Which in vitro dissolution conditions are recited in US 8,771,739?

Claim 1 requires dissolution-test formation of a homogeneous particle suspension, then dependent claims narrow the dissolution environment.

pH windows

Claim 5: Suspension in vitro at pH 4.0 to pH 8.0.
Claim 6: Narrower window pH 5.5 to pH 7.5.

Acid pre-treatment step

Claims 7-8: Include an acidic pre-treatment step as part of dissolution testing.
Claims 9-10: Acid pre-treatment is suspension in dissolution medium at pH ~1.2 for ~20 minutes.

Business implication: These dependent claims can be used to argue that only formulations that maintain the intended suspension behavior under specific gastrointestinal-relevant stress conditions are covered.

What manufacturing method is protected: spray drying and specified solvents?

Spray-drying requirement

Claim 11: Solid dispersion is formed by spray drying.

Solvent list (dependent)

Claim 12: Prior to dispersion of itraconazole, the polymer is dispersed in one or more of:
- methylene chloride, chloroform, ethanol, methanol, propan-2-ol, ethyl acetate, acetone, and water.

Process claims track steps

Claim 19: Process includes:
- (a) add HPMCP to a solvent to form a dispersion,
- (b) add itraconazole to the dispersion to form a solution,
- (c) spray dry to form the solid dispersion.
Claims 20-22: Specify methylene chloride as solvent (dependent) and optional subsequent blending with excipients to produce a powder.
Claims 23-24: Blending can occur with grinding.

Business implication: The manufacturing method and solvent selections can define both validity and infringement defenses, particularly for a licensee considering alternate processing routes (different polymer dispersion media, different drying method, or post-processing particle engineering).

How is bioavailability quantified in US 8,771,739 and what performance tests are cited?

Relative bioavailability

Claim 13: Bioavailability of itraconazole in the composition is at least twice itraconazole “per se.”

Reduced food effect

Claim 14: Composition has a reduced food effect compared to itraconazole per se.

Absolute AUC target tied to dose and fasting

Claim 25: Composition provides mean AUC ≥800 ng·h/mL after administration of 100 mg itraconazole in fasted state.

Business implication: These claims combine formulation structure with clinical exposure benchmarks. In litigation, performance data can become a central evidentiary axis for both infringement and invalidity challenges (enablement, written description, and anticipation based on prior art that already met these exposures).

What is the claim coverage breadth across composition, dosage form, and process?

Claim scope tier	Claims	Coverage character
Composition (core)	1	Solid dispersion itraconazole + HPMCP; ratio 1:1 to 1:3; dissolution forms homogeneous particle suspension; performance AUC ≥800 (mean) in fasted state
Particle/suspension morphology (dependent)	2-4	Cloudiness via diffraction; size bounds (<10 µm and >1 nm); nano presence; cloudiness persists after 450 nm filtration
Dissolution conditions (dependent)	5-10	pH ranges 4.0-8.0 and 5.5-7.5; optional acid pre-treatment pH ~1.2 for ~20 min
Manufacturing (dependent composition)	11-12	Spray drying; polymer dispersion solvent selections
Performance add-ons (dependent)	13-14, 25	≥2x relative bioavailability; reduced food effect; AUC threshold at 100 mg fasted
Dosage forms (dependent)	15-18	Capsule/tablet containing therapeutically effective amount and typical excipients
Process claims	19-24	Stepwise method to prepare solid dispersion, including solvent (dependent methylene chloride), spray drying, and blending/grinding to powder

Net effect: The patent can be asserted against (1) product formulations matching the structural and suspension behaviors, (2) marketed dosage forms containing such formulations, and (3) manufacturing workflows that follow the stated process steps with specified solvent and spray drying.

How strong is the “claim hook”: what portions are most restrictive versus most general?

Most restrictive features (useful for validity differentiation)

HPMCP requirement (Claim 1): narrows polymer choice.
itraconazole:polymer ratio 1:1 to 1:3 (Claim 1).
AUC ≥800 ng·h/mL fasted (Claim 1 and Claim 25).
Cloudiness and filtration behavior (Claim 2 and Claim 4), including retention of cloudiness after 450 nm filtration.
Specific dissolution conditions (pH windows; acid pre-treatment pH ~1.2 for ~20 minutes).
Spray drying (Claim 11).
Solvent list in polymer dispersion (Claim 12) and methylene chloride option (Claim 20).

More general features (useful for infringement arguments)

“Pharmaceutical dosage form” plus common excipients (Claims 15-18).
“Suspension forms homogeneous dispersion of particles” during dissolution testing (Claim 1).

Litigation tactic (typical): A patentee usually pleads the independent claim plus selected dependents that map to product characterization and dissolution testing, then uses dependent features to defeat design-arounds. Conversely, a defendant may attempt to show either (a) they do not have the same HPMCP-based solid dispersion with the same ratio and suspension behavior, or (b) the clinical exposure target (AUC) is not met, or (c) their manufacturing route avoids spray drying / relevant solvent steps.

What generic entry risks exist for itraconazole products if they try to match exposure targets using different polymers or processing?

Risk concentration

The highest risk is for products that:

use HPMCP specifically,
produce a spray-dried solid dispersion,
maintain ratio within 1:1 to 1:3,
produce suspensions that remain cloudy after 450 nm filtration (if aiming to match dissolution behavior),
and demonstrate clinical performance meeting the AUC ≥800 ng·h/mL fasted benchmark.

Plausible design-around directions (based on the claim text)

Replace HPMCP with a different acidic functional polymer (likely avoids Claim 1’s polymer limitation).
Move away from spray drying (avoid Claim 11 and process claims 19-24).
Use different itraconazole:polymer ratio outside 1:1 to 1:3.
Engineer particles so suspension clears after 450 nm filtration (target Claim 4 avoidance) while still attempting to meet dissolution performance through other mechanisms.
Avoid the specific dissolution pre-treatment behavior in product characterization (may not eliminate Claim 1, but can weaken dependent-claim match).

Business implication: Any license strategy or litigation defense focusing on “same exposure” must also address the claim’s formulation-specific constraints. Performance-driven arguments alone are less effective if particle-scale, polymer, ratio, or manufacturing step limitations are not met.

How does this patent compare claim-by-claim with typical solid-dispersion itraconazole strategies?

Typical competitors in the itraconazole solid-dispersion space commonly vary by polymer type (solubilizers, enteric polymers), drying methods, and particle engineering. This patent is distinctive in that it:

locks the polymer identity to HPMCP,
includes explicit ratio and AUC threshold language,
and codifies particle-scale behaviors (cloudiness/diffraction and 450 nm filtration persistence) that go beyond generic “improved solubility” recitations.

From an enforcement standpoint, that combination makes the patent easier to map to:

product characterization data (particle size distribution; filtration tests; diffraction/cloudiness),
dissolution testing protocols (pH and acid pre-treatment),
and clinical exposure data (fasted AUC, relative bioavailability, food effect).

What is the claim coverage for “dose forms” and does it create packaging-level infringement leverage?

Claims 15-18 extend protection to:

dosage forms containing therapeutically effective amounts of the protected composition,
with excipients from a standard set,
and dosage form types limited to capsule or tablet.

Practical effect: A manufacturer cannot avoid liability simply by changing capsule/tablet excipients; it must avoid having the underlying protected Claim 1 composition.

What licensing or litigation posture is implied by the claim structure?

Composition and performance are tied together

Because Claim 1 and Claim 25 include clinical exposure targets, licensing disputes can hinge on comparative bioavailability and food effect. In litigation, the parties often frame arguments around:

matching formulation structure (polymer identity, ratio, spray dried solid dispersion),
and whether the accused product meets the AUC threshold.

Manufacturing route creates additional leverage

Process claims (19-24) create an additional theory: even if a defendant argues that their final product differs, matching process steps and solvent use can be used to establish infringement.

Key Takeaways

US 8,771,739 protects an itraconazole solid dispersion with HPMCP, constrained to an itraconazole:polymer ratio of 1:1 to 1:3 and a fasted mean AUC ≥800 ng·h/mL.
The strongest dependent-claim hooks are particle-scale cloudiness behavior (diffracting particles, remaining cloudy after 450 nm filtration) and specific dissolution testing conditions (pH windows and pH ~1.2 for ~20 minutes acid pre-treatment).
The patent also covers spray-drying manufacturing and (in dependent claims) polymer dispersion solvent choices, including methylene chloride.
Dosage form claims cover capsules and tablets containing the protected composition with standard excipients; design-arounds must avoid the underlying protected composition rather than relying on excipient swaps.
Any attempt to engineer around must address polymer identity (HPMCP), ratio window, solid dispersion formation method, suspension behavior, and exposure performance metrics.

FAQs

1) What does “solid dispersion” mean in the context of US 8,771,739?

The claims require itraconazole and HPMCP in a solid-dispersion state, formed by spray drying (Claim 11) and characterized by dissolution-time formation of a homogeneous particle suspension (Claim 1).

2) Does the patent protect itraconazole particle sizes above 1 nm only, or all sizes?

The dependent claims set lower bounds: particle size is >1 nm (Claims 2-4). Cloudiness after 450 nm filtration further implies a nano-size population.

3) Is acid pre-treatment required to practice within the patent scope?

No. Acid pre-treatment is required only for dependent claims (Claims 7-10). Claim 1 covers dissolution behavior generally, with pH-linked dependents.

4) Can a product avoid infringement by using a different polymer instead of HPMCP?

Claim 1 requires the polymer comprises hydroxypropyl methylcellulose phthalate. Using a different polymer would generally avoid the literal polymer limitation of Claim 1.

5) What clinical metric is used as an exposure benchmark?

The patent uses an absolute performance metric: mean AUC ≥800 ng·h/mL after administration of 100 mg itraconazole in the fasted state (Claims 1 and 25).

References

US Patent 8,771,739.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Australia	PQ4854	Dec 23, 1999
Australia	PQ7450	May 12, 2000

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2331801	⤷ Start Trial
Australia	7252900	⤷ Start Trial
Australia	782469	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 8,771,739